ArticleBiomedical chromatography : BMC2026
Mechanistic Insights Into the Anti-Constipation Potential of Xiaogan Jianwei Formula: Integration of HPLC-Q-TOF MS/MS, Network Pharmacology, In Vivo Validation, and Gut Microbiota.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aims to explore the mechanism of action and potential bioactive constituents of Xiaogan Jianwei Formula (XG) in the treatment of constipation. The chemical constituents of XG and its absorbable components were characterized using HPLC-Q-TOF MS/MS, and network pharmacology was used to predict key targets and pathways, identifying the cAMP/PKA signaling pathway as a target pathway. In vivo experiments were performed to evaluate anti-constipation effects, including measurements of fecal water content, intestinal transit rate, MUC2 expression, cAMP/PKA/AQP3 signaling, and gut microbiota composition via 16S rRNA sequencing. In total, 138 chemical constituents were identified from XG, of which 32 components were absorbable; flavonoids were the main active ingredients. Pharmacological studies showed that XG significantly increased fecal water content and intestinal transit rate in loperamide-induced constipated rats without affecting physiological parameters. XG upregulated the expression of cAMP, PKA, p-PKA, and AQP3 and restored MUC2 expression. Moreover, XG improved gut microbiota diversity, enriched beneficial bacteria such as Akkermansia, and reduced pathogenic taxa like Helicobacter and Campylobacterota. XG alleviates constipation by regulating the cAMP/PKA/AQP3 signaling axis and modulating the gut microbiota. This study provides a scientific basis for the clinical application of XG and supports its development as an effective medicine for constipation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.